Acute kidney injury: Difference between revisions
No edit summary |
|||
| Line 2: | Line 2: | ||
*Majority of cases of community-acquired ARF is secondary to volume depletion | *Majority of cases of community-acquired ARF is secondary to volume depletion | ||
===RIFLE Classification=== | ===RIFLE Classification=== | ||
*Risk - Serum Cr increased 1.5x baseline | |||
*Injury - Serum Cr increased 2.0x baseline | |||
*Failure - Serum Cr increased 3.0x baseline OR Cr >4 and acute increase >0.5 | |||
*Loss - Complete loss of kidney function for >4wk | |||
*[[ESRD]] - Need for renal replacement therapy for >3mo | |||
===Chronic Kidney Disease Stages=== | ===Chronic Kidney Disease Stages=== | ||
*Useful if pt's baseline creatinine is unknown | *Useful if pt's baseline creatinine is unknown | ||
| Line 16: | Line 16: | ||
==Risk Factors== | ==Risk Factors== | ||
*[[Contrast-Induced Nephropathy|Radiocontrast agents]] | |||
**Esp if GFR <60, hypovolemic | |||
*Atherosclerosis | |||
*Chronic hypertension | |||
*Chronic kidney disease | |||
*NSAIDs | |||
*ACEI/ARB | |||
*[[Sepsis]] | |||
*[[Hypercalcemia]] | |||
*Hepatorenal syndrome | |||
==Etiology== | ==Etiology== | ||
===Prerenal=== | ===Prerenal=== | ||
*Hypovolemia | |||
**GI: decreased intake, vomiting and diarrhea | |||
**Pharmacologic: diuretics | |||
**Third spacing | |||
***[[Pancreatitis]] | |||
**Skin losses: fever, burns | |||
**Miscellaneous | |||
***Hypoaldosteronism | |||
***Salt-losing nephropathy | |||
***Postobstructive diuresis | |||
*[[Hypotension]] | |||
**Septic vasodilation | |||
**Hemorrhage | |||
**Decreased cardiac output | |||
***Ischemia/infarction | |||
***Valvulopathy | |||
**Pharmacologic | |||
***B-blockers | |||
***CCBs | |||
***Antihypertensive medications | |||
**High-output failure | |||
***[[Thyrotoxicosis]] | |||
***AV fistula | |||
*Renal artery and small-vessel disease | |||
**Embolism: thrombotic, septic, cholesterol | |||
**Thrombosis: atherosclerosis, vasculitis, sickle cell disease | |||
**Dissection | |||
**Pharmacologic | |||
***NSAIDs | |||
***ACEI/ARB | |||
****Observed shortly after initiation of therapy | |||
**Microvascular thrombosis | |||
***Preeclampsia | |||
***HUS | |||
***DIC | |||
***vasculitis | |||
***SCD | |||
**Hypercalcemia | |||
===Intrinsic=== | ===Intrinsic=== | ||
*Tubular diseases | |||
**Ischemic acute tubular necrosis | |||
***Caused by more advanced disease due to the prerenal causes | |||
*Nephrotoxins | |||
**Aminoglycosides, [[Contrast-Induced Nephropathy|radiocontrast]], amphotericin, heme pigments ([[rhabdo, hemolysis) | |||
**Obstruction | |||
***Uric acid, calcium oxalate, myeloma, amyloid | |||
***Pharmacologic: sulfonamide, triamterene, acyclovir, indinavir | |||
*Interstitial diseases | |||
**Acute interstitial nephritis: typically a drug reaction (NSAIDs, abx, phenytoin) | |||
**Infection: bilateral pyelonephritis, Legionnaire disease, hantavirus | |||
**Infiltrative disease: sarcoidosis, lymphoma | |||
**Autoimmune diseases: SLE | |||
*Glomerular diseases | |||
**Rapidly progressive glomerulonephritis | |||
***Goodpasture, Wegener granulomatosis, HSP, SLE, membranoproliferative GN | |||
**Postinfectious glomerulonephritis | |||
*Small-vessel diseases | |||
**Microvascular thrombosis | |||
***Preeclampsia, [[HUS]], [[DIC]], [[TT]]P, vasculitis (PAN, SCD, atheroembolism) | |||
**Malignant hypertension | |||
**Scleroderma | |||
**Renal vein thrombosis | |||
===Postrenal=== | ===Postrenal=== | ||
*Infants and children | |||
**Urethra and bladder outlet | |||
***Anatomic malformations | |||
****Urethral atresia | |||
****Meatal stenosis | |||
****Anterior and posterior urethral valves | |||
**Ureter | |||
***Anatomic malformations | |||
****Vesicoureteral reflux (female preponderance) | |||
****Ureterovesical junction obstruction | |||
****Ureterocele | |||
****Retroperitoneal tumor | |||
*All ages | |||
**Various locations in GU tract | |||
***Trauma | |||
***Blood clot | |||
**Urethra and bladder outlet | |||
***Phimosis or urethral stricture (male preponderance) | |||
***Neurogenic bladder | |||
****DM, spinal cord disease, multiple sclerosis, Parkinson's | |||
****Pharmacologic: anticholinergics, a-adrenergic antagonists, opiates | |||
*Adults | |||
**Urethra and bladder outlet | |||
***BPH | |||
***Cancer of prostate, bladder, cervix, or colon | |||
***Obstructed catheters | |||
**Ureter | |||
***Calculi, uric acid crystals | |||
***Papillary necrosis | |||
****SCD, DM, pyelonephritis | |||
***Tumor: Ureter, uterus, prostate, bladder, colon, rectum; retroperitoneal lymphoma | |||
***Retroperitoneal fibrosis: idiopathic, tuberculosis, sarcoidosis, propranolol | |||
***Stricture: TB, radiation, schistosomiasis, NSAIDs | |||
***Miscellaneous | |||
****Aortic aneurysm | |||
****Pregnant uterus | |||
****IBD | |||
****Trauma | |||
==Clinical Features== | ==Clinical Features== | ||
| Line 157: | Line 157: | ||
==Diagnosis== | ==Diagnosis== | ||
*Prerenal | |||
**BUN/Cr ratio > 20 | |||
**FeNa <1% ((urine sodium/plasma sodium) / (urine creatinine / serum creatinine)) | |||
***< 2% for neonates | |||
**Urine osm >500 | |||
**Urine sodium < 20 mEq/L | |||
**Specific gravity > 1.020 | |||
**Fractional excretion of urea < 35% | |||
**Microscopic analysis | |||
***Hyaline casts | |||
*Instrinsic | |||
**FeNa >1% | |||
***> 2.5% for neonates | |||
**Urine Osm <350 | |||
**Urine sodium > 40 mEq/L | |||
**Specific gravity < 1.020 | |||
**Fractional excretion of urea > 50% | |||
**Microscopic analysis | |||
***Acute glomerulonephritis: RBCs, casts | |||
***Acute tubular necrosis: protein, tubular epithelial cells | |||
*Postrenal | |||
**FeNa >1% | |||
**Urine Osm <350 | |||
==Work-up== | ==Work-up== | ||
*Urine | |||
*Prostate exam | |||
*UA, urine sodium, urine creatinine, urine urea | |||
*ECG (hyperkalemia) | |||
===Imaging=== | ===Imaging=== | ||
*CXR | |||
*Evidence of volume overload, PNA | |||
*US | |||
**Test of choice in setting of acute renal failure | |||
**Bladder size (post-void) | |||
**Hydronephrosis | |||
**IVC collapsibility (prerenal) | |||
*CT | |||
**Useful to determine cause of post renal failure (identification of abdominal masses etc.) | |||
**Should generally not be used with IV contrast due to potential risk for [[Contrast-Induced Nephropathy|CIN]] | |||
**Indicated if hydronephrois found on US in order to define the location of obstruction | |||
==Treatment== | ==Treatment== | ||
*Treat underlying cause | |||
*IVF (prerenal) | |||
*Obstruction | |||
**Note: Postobstructive diuresis can result in significant volume loss and death | |||
***Typically occurs when obstruction has been prolonged / has resulted in renal failure | |||
***Admit pts w/ persistent diuresis of >250 mL/h for >2hr | |||
**Foley Catheter, consider [[Coude Catheter]] | |||
**Suprapubic (if Coude fails) | |||
*Dialysis | |||
**Indicated for: | |||
***A: Acidosis (severe) | |||
***E: Electrolyte abnormality (e.g. uncontrolled hyperkalemia) | |||
***I: Ingestions (lithium, ASA, methanol, ethylene glycol, theophylline) | |||
***O: Overload (volume) w/ persistent hypoxia | |||
***U: Uremic pericarditis/encephalopathy/bleeding dyscrasia | |||
***Also: | |||
****Na <115 or >165 mEq/L | |||
****BUN >100 | |||
==Disposition== | ==Disposition== | ||
Revision as of 03:16, 6 May 2015
Background
- Majority of cases of community-acquired ARF is secondary to volume depletion
RIFLE Classification
- Risk - Serum Cr increased 1.5x baseline
- Injury - Serum Cr increased 2.0x baseline
- Failure - Serum Cr increased 3.0x baseline OR Cr >4 and acute increase >0.5
- Loss - Complete loss of kidney function for >4wk
- ESRD - Need for renal replacement therapy for >3mo
Chronic Kidney Disease Stages
- Useful if pt's baseline creatinine is unknown
- Stage 1: Kidney damage (e.g. proteinuria) and normal GFR; GFR >90
- Stage 2: Kidney damage (e.g. proteinuria) and mild decr in GFR; GFR 60-89
- Stage 3: Moderate decrease in GFR; GFR >30-59
- Stage 4: Severe decrease in GFR; GFR 15-29
- Stage 5: Kidney failure (dialysis or kidney transplant needed); GFR <15
Risk Factors
- Radiocontrast agents
- Esp if GFR <60, hypovolemic
- Atherosclerosis
- Chronic hypertension
- Chronic kidney disease
- NSAIDs
- ACEI/ARB
- Sepsis
- Hypercalcemia
- Hepatorenal syndrome
Etiology
Prerenal
- Hypovolemia
- GI: decreased intake, vomiting and diarrhea
- Pharmacologic: diuretics
- Third spacing
- Skin losses: fever, burns
- Miscellaneous
- Hypoaldosteronism
- Salt-losing nephropathy
- Postobstructive diuresis
- Hypotension
- Septic vasodilation
- Hemorrhage
- Decreased cardiac output
- Ischemia/infarction
- Valvulopathy
- Pharmacologic
- B-blockers
- CCBs
- Antihypertensive medications
- High-output failure
- Thyrotoxicosis
- AV fistula
- Renal artery and small-vessel disease
- Embolism: thrombotic, septic, cholesterol
- Thrombosis: atherosclerosis, vasculitis, sickle cell disease
- Dissection
- Pharmacologic
- NSAIDs
- ACEI/ARB
- Observed shortly after initiation of therapy
- Microvascular thrombosis
- Preeclampsia
- HUS
- DIC
- vasculitis
- SCD
- Hypercalcemia
Intrinsic
- Tubular diseases
- Ischemic acute tubular necrosis
- Caused by more advanced disease due to the prerenal causes
- Ischemic acute tubular necrosis
- Nephrotoxins
- Aminoglycosides, radiocontrast, amphotericin, heme pigments ([[rhabdo, hemolysis)
- Obstruction
- Uric acid, calcium oxalate, myeloma, amyloid
- Pharmacologic: sulfonamide, triamterene, acyclovir, indinavir
- Interstitial diseases
- Acute interstitial nephritis: typically a drug reaction (NSAIDs, abx, phenytoin)
- Infection: bilateral pyelonephritis, Legionnaire disease, hantavirus
- Infiltrative disease: sarcoidosis, lymphoma
- Autoimmune diseases: SLE
- Glomerular diseases
- Rapidly progressive glomerulonephritis
- Goodpasture, Wegener granulomatosis, HSP, SLE, membranoproliferative GN
- Postinfectious glomerulonephritis
- Rapidly progressive glomerulonephritis
- Small-vessel diseases
Postrenal
- Infants and children
- Urethra and bladder outlet
- Anatomic malformations
- Urethral atresia
- Meatal stenosis
- Anterior and posterior urethral valves
- Anatomic malformations
- Ureter
- Anatomic malformations
- Vesicoureteral reflux (female preponderance)
- Ureterovesical junction obstruction
- Ureterocele
- Retroperitoneal tumor
- Anatomic malformations
- Urethra and bladder outlet
- All ages
- Various locations in GU tract
- Trauma
- Blood clot
- Urethra and bladder outlet
- Phimosis or urethral stricture (male preponderance)
- Neurogenic bladder
- DM, spinal cord disease, multiple sclerosis, Parkinson's
- Pharmacologic: anticholinergics, a-adrenergic antagonists, opiates
- Various locations in GU tract
- Adults
- Urethra and bladder outlet
- BPH
- Cancer of prostate, bladder, cervix, or colon
- Obstructed catheters
- Ureter
- Calculi, uric acid crystals
- Papillary necrosis
- SCD, DM, pyelonephritis
- Tumor: Ureter, uterus, prostate, bladder, colon, rectum; retroperitoneal lymphoma
- Retroperitoneal fibrosis: idiopathic, tuberculosis, sarcoidosis, propranolol
- Stricture: TB, radiation, schistosomiasis, NSAIDs
- Miscellaneous
- Aortic aneurysm
- Pregnant uterus
- IBD
- Trauma
- Urethra and bladder outlet
Clinical Features
- Acute renal failure itself has few symptoms until severe uremia develops:
- N/V, drowsiness, fatigue, confusion, coma
- Pts more likely to present w/ symptoms related to underlying cause:
- Prerenal
- Thirst, orthostatic light-headedness, decreasing urine output
- Intrinsic
- Flank pain, hematuria
- Nephrolithiasis
- Papillary necrosis
- Crystal-induced nephropathy
- Myalgias, seizures, recreational intoxication
- Pigment-induced ARF (rhabdo)
- Darkening urine and edema (esp w/ preceding pharyngitis or cutaneous infection)
- Acute glomerulonephritis
- Fever, arthralgia, rash
- Acute interstitial nephritis
- Cough, dyspnea, hemoptysis
- Goodpasture, Wegener granulomatosis
- Flank pain, hematuria
- Postrenal
- Alternating oliguria and polyuria is pathognomonic of obstruction
- Anuria
- Prerenal
Diagnosis
- Prerenal
- BUN/Cr ratio > 20
- FeNa <1% ((urine sodium/plasma sodium) / (urine creatinine / serum creatinine))
- < 2% for neonates
- Urine osm >500
- Urine sodium < 20 mEq/L
- Specific gravity > 1.020
- Fractional excretion of urea < 35%
- Microscopic analysis
- Hyaline casts
- Instrinsic
- FeNa >1%
- > 2.5% for neonates
- Urine Osm <350
- Urine sodium > 40 mEq/L
- Specific gravity < 1.020
- Fractional excretion of urea > 50%
- Microscopic analysis
- Acute glomerulonephritis: RBCs, casts
- Acute tubular necrosis: protein, tubular epithelial cells
- FeNa >1%
- Postrenal
- FeNa >1%
- Urine Osm <350
Work-up
- Urine
- Prostate exam
- UA, urine sodium, urine creatinine, urine urea
- ECG (hyperkalemia)
Imaging
- CXR
- Evidence of volume overload, PNA
- US
- Test of choice in setting of acute renal failure
- Bladder size (post-void)
- Hydronephrosis
- IVC collapsibility (prerenal)
- CT
- Useful to determine cause of post renal failure (identification of abdominal masses etc.)
- Should generally not be used with IV contrast due to potential risk for CIN
- Indicated if hydronephrois found on US in order to define the location of obstruction
Treatment
- Treat underlying cause
- IVF (prerenal)
- Obstruction
- Note: Postobstructive diuresis can result in significant volume loss and death
- Typically occurs when obstruction has been prolonged / has resulted in renal failure
- Admit pts w/ persistent diuresis of >250 mL/h for >2hr
- Foley Catheter, consider Coude Catheter
- Suprapubic (if Coude fails)
- Note: Postobstructive diuresis can result in significant volume loss and death
- Dialysis
- Indicated for:
- A: Acidosis (severe)
- E: Electrolyte abnormality (e.g. uncontrolled hyperkalemia)
- I: Ingestions (lithium, ASA, methanol, ethylene glycol, theophylline)
- O: Overload (volume) w/ persistent hypoxia
- U: Uremic pericarditis/encephalopathy/bleeding dyscrasia
- Also:
- Na <115 or >165 mEq/L
- BUN >100
- Indicated for:
Disposition
Admit
See Also
Source
Tintinalli
